- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Interventions
- Selinexor, Clarithromycin, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Brooklyn, New York • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma
- Interventions
- Bendamustine, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Cristina Gasparetto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Kaposi Sarcoma
- Interventions
- liposomal doxorubicin, pomalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- dexamethasone, clarithromycin, Pomalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Pomalidomide Oral Product, Placebo oral capsule
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Los Alamitos, California • Torrance, California • Whittier, California + 5 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- SEA-BCMA, dexamethasone, pomalidomide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 13
- States / cities
- Palo Alto, California • Aurora, Colorado • Miami, Florida + 10 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- AMG 701, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 12 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Coeur d'Alene, Idaho • Omaha, Nebraska
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Interventions
- INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide, INCB050465, INCB039110
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
- Conditions
- Central Nervous System Neoplasms, Medulloblastoma
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Burbank, California • Encinitas, California • Fresno, California + 5 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Marizomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Plasma Cell Myeloma
- Interventions
- Belantamab Mafodotin, Dexamethasone, Pomalidomide
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
- Interventions
- Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- San Diego, California • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- pomalidomide, dexamethasone, rituximab
- Drug
- Lead sponsor
- Steven P. Treon, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anemia, Sickle Cell
- Interventions
- pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan